These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19144760)

  • 1. Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
    Wenzel RR; Littke T; Kuranoff S; Jürgens C; Bruck H; Ritz E; Philipp T; Mitchell A;
    J Am Soc Nephrol; 2009 Mar; 20(3):655-64. PubMed ID: 19144760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avosentan for overt diabetic nephropathy.
    Mann JF; Green D; Jamerson K; Ruilope LM; Kuranoff SJ; Littke T; Viberti G;
    J Am Soc Nephrol; 2010 Mar; 21(3):527-35. PubMed ID: 20167702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention.
    Baltatu OC; Zaugg CE; Schumacher C; Louie P; Campos LA; Bader M
    Pharmacol Res; 2014 Feb; 80():9-13. PubMed ID: 24368192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.
    Watson AM; Li J; Schumacher C; de Gasparo M; Feng B; Thomas MC; Allen TJ; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2010 Jan; 53(1):192-203. PubMed ID: 19862499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of congestive heart failure after treatment with an endothelin receptor antagonist.
    Hoekman J; Lambers Heerspink HJ; Viberti G; Green D; Mann JF; de Zeeuw D
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):490-8. PubMed ID: 24408122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
    Chen Y; Liu P; Chen X; Li Y; Zhang F; Wang Y
    Am J Med Sci; 2018 May; 355(5):418-424. PubMed ID: 29753370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
    Kohan DE; Pollock DM
    Br J Clin Pharmacol; 2013 Oct; 76(4):573-9. PubMed ID: 23228194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
    Kohan DE; Pritchett Y; Molitch M; Wen S; Garimella T; Audhya P; Andress DL
    J Am Soc Nephrol; 2011 Apr; 22(4):763-72. PubMed ID: 21372210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
    Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
    Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
    Mazerska M; Myśliwiec M
    Adv Med Sci; 2009; 54(1):37-40. PubMed ID: 19505872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Protective Effects of Combination of Diltiazem and ACEI/ARB on the Progression of Diabetic Nephropathy: Randomized Controlled Trial.
    Krairittichai U; Sarinnapakorn V; Mahannopkul R; Ainwan P
    J Med Assoc Thai; 2017 Feb; 100 Suppl 1():S40-7. PubMed ID: 29927180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
    de Zeeuw D; Coll B; Andress D; Brennan JJ; Tang H; Houser M; Correa-Rotter R; Kohan D; Lambers Heerspink HJ; Makino H; Perkovic V; Pritchett Y; Remuzzi G; Tobe SW; Toto R; Viberti G; Parving HH
    J Am Soc Nephrol; 2014 May; 25(5):1083-93. PubMed ID: 24722445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.
    Gagliardini E; Corna D; Zoja C; Sangalli F; Carrara F; Rossi M; Conti S; Rottoli D; Longaretti L; Remuzzi A; Remuzzi G; Benigni A
    Am J Physiol Renal Physiol; 2009 Nov; 297(5):F1448-56. PubMed ID: 19675181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system.
    Cotter J; Oliveira P; Cunha P; Polónia J
    Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
    Krimholtz MJ; Karalliedde J; Thomas S; Bilous R; Viberti G
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S42-7. PubMed ID: 15938033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.